Abstract
Background and aims: We discovered that plasma corticotrophin releasing factor (CRF) levels in the young rats with hypoxic-ischemia (HI) brain damage were changeable, which was related with the time of HI. In present study, we will explore the effects of CRF acceptor 1 (CRF-R1) antagonist CP-154,526 (CP) and Ca2+ ion pathway antagonist Verapamil (VP) on plasma CRF secreting levels in the young rats after hypoxic-ischemia for one day.
Methods: Eighty young rats were randomly divided into eight groups, the normal control groups, sham operated groups, CP control groups, VP control groups, model groups, HI+CP groups, HI+VP groups and HI+CP+VP groups are set. Plasma CRF levels of young rats in all groups were measured by radioimmunoassay.
Results: Compared with the normal control groups, sham operated groups, CP control groups, VP control groups, plasma CRF levels in the model groups, HI+CP groups, HI+VP groups and HI+CP+VP groups all significantly decreased (P Values all than less 0.001). Compared with the HI groups, plasma CRF levels in the HI+CP groups (P<0.05) and HI+VP groups (P<0.001) all significantly increased. Compared with the HI+CP groups, plasma CRF levels in the HI+VP groups (P<0.001) significantly increased. Compared with the HI+VP groups, plasma CRF levels in the HI+CP+VP groups (P<0.001) significantly decreased.
Conclusions: CRF-R1 antagonist CP or Ca2+ ion pathway antagonist VP can promote CRF secreting levels in the young rats after hypoxic-ischemia for one day, but when the CP and VP were simultaneously used, and CP can deteriorate the CRF secreting levels.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dong, J., Zhu, Y., Zhou, W. et al. Effects Of CP-154,526 and Verapamil on Corticotrophin Releasing Factor Secreting Levels. Pediatr Res 70 (Suppl 5), 169 (2011). https://doi.org/10.1038/pr.2011.394
Issue Date:
DOI: https://doi.org/10.1038/pr.2011.394
- Springer Nature America, Inc.